Scarica l'app Stockscreener
17.82
0.22%
0.04
Precedente Chiudi:
$17.78
Aprire:
$17.79
Volume 24 ore:
2.50M
Relative Volume:
0.81
Capitalizzazione di mercato:
$56.30B
Reddito:
$29.85B
Utile/perdita netta:
$776.90M
Rapporto P/E:
74.00
EPS:
0.2408
Flusso di cassa netto:
$4.35B
1 W Prestazione:
-1.44%
1M Prestazione:
-3.10%
6M Prestazione:
+26.92%
1 anno Prestazione:
+21.14%
Intervallo 1D:
$17.79
$17.98
Intervallo di 1 settimana:
$17.61
$17.98
Portata 52W:
$12.99
$18.89
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK vs ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 56.30B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
122.38 | 51.46B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.75 | 43.42B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.40 | 37.73B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
588.38 | 25.79B | 3.18B | 1.33B | 1.04B | 27.90 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2026-01-13 | Ripresa | Morgan Stanley | Overweight |
| 2025-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-07-19 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-10-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-01 | Iniziato | Cowen | Market Perform |
| 2019-08-15 | Downgrade | Daiwa Securities | Outperform → Neutral |
Mostra tutto
Takeda Pharmaceutical Co Adr Borsa (TAK) Ultime notizie
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
Takeda Pharmaceutical Co Ltd (HAM:TKDA) Competitors 2026 - GuruFocus
Takeda Pharmaceutical Co Ltd Stock Operating Data - GuruFocus
TAK Stock Price, Quote & Chart | TAKEDA PHARMACEUTIC-SP ADR (NYSE:TAK) - ChartMill
Takeda Pharmaceutical Co Ltd stock: What you should know now for smart investing - AD HOC NEWS
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Benzinga
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance Singapore
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Takeda Pharmaceutical Co Ltd (HAM:TKDA) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Takeda Pharmaceutical (ADR) Stock: A Stable Global Pharma Play with Focus on Oncology and Rare Disea - AD HOC NEWS
Who's Buying or Selling Takeda Pharmaceutical Co Ltd (HAM:TKDA) Stock Today? - gurufocus.com
Takeda Pharmaceutical Co Ltd Stock Intrinsic Values | HAM:TKDA - GuruFocus
Takeda Pharmaceutical Co Ltd Stock Historical Valuations | HAM:TKDA - GuruFocus
Takeda Pharmaceutical Co Ltd (LTS:0A87) Bonds - GuruFocus
Takeda Pharmaceutical stock faces pressure from geopolitical risks amid pipeline advances - AD HOC NEWS
Takeda Pharmaceutical (ADR) stock faces pressure amid pipeline setbacks and competitive oncology cha - AD HOC NEWS
Takeda Pharmaceutical (ADR) Stock Steady Amid Pharma Sector Volatility as Investors Eye Pipeline Pro - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA)Valuation Measures & Financial Statistics - GuruFocus
FDA Grants Priority Review for Takeda (TAK) and Protagonist's Rusfertide in PV Treatment - Finviz
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Takeda Stock: Quiet Japan Pharma With a Big U.S. Pipeline Bet - AD HOC NEWS
Takeda Stock: Quiet Pharma Giant That US Investors Keep Missing - AD HOC NEWS
Takeda Pharmaceutical ADR sees IBD RS rating climb to 76 - MSN
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - Finviz
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Earnings call transcript: Takeda beats Q3 2025 forecasts, stock climbs - Investing.com
Takeda Pharmaceutical ADR: Defensive Pharma Giant Tests Investor Patience as Shares Drift Near Lows - AD HOC NEWS
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? - Finviz
Argenx SE – ADR (ARGX) Sentiments Bolstered on Vyvgart FDA Priority Review Milestone - Yahoo Finance
Takeda Pharma ADR earnings beat by $0.04, revenue topped estimates - Investing.com Australia
Stocks To Watch: Takeda Pharmaceutical ADR Sees Relative Strength Rating Rise To 83 - Investor's Business Daily
Takeda Q3 FY2025 slides: Revenue dips 3.3% as company preps key 2026 launches - Investing.com
Earnings call transcript: Takeda Pharma Q3 2026 sees mixed performance - Investing.com
Apple, Visa, KLA-Tencor and more set to report earnings Thursday By Investing.com - Investing.com Nigeria
Takeda Pharmaceutical ADR Gets Technical Rating Upgrade - Investor's Business Daily
Takeda Pharmaceutical Co Adr Azioni (TAK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):